SDG indicator 3.b.3 - an analysis of its robustness and challenges for measuring access to medicines for children.

导出 OA

翻译打印收藏纠错

作者： I R,Joosse ^[1] ; V J,Wirtz ^[2] ; A T,van Mourik ^[1] ; B A,Wagner ^[1] ; A K,Mantel-Teeuwisse ^[1] ; F,Suleman ^[3] ; H A,van den Ham ^[4]

作者单位： Utrecht WHO Collaborating Centre for Pharmaceutical Policy and Regulation, Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences (UIPS), Utrecht University, Universiteitsweg 99, 3584 CG, Utrecht, the Netherlands. ^[1] WHO Collaborating Centre in Pharmaceutical Policy, Department of Global Health, Boston University School of Public Health, Boston, USA. ^[2] WHO Collaborating Centre for Pharmaceutical Policy and Evidence Based Practice, School of Health Sciences, University of KwaZulu-Natal, Durban, South Africa. ^[3] Utrecht WHO Collaborating Centre for Pharmaceutical Policy and Regulation, Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences (UIPS), Utrecht University, Universiteitsweg 99, 3584 CG, Utrecht, the Netherlands. h.a.vandenham@uu.nl. ^[4]

关键词 Access to medicines Affordability Availability Child health Child medicines Indicator Sustainable development goals

主题词成年人(Adult);人类(Humans);卫生服务易得程度(Health Services Accessibility);药物, 必备(Drugs, Essential);患病代价(Cost of Illness)

DOI 10.1186/s12913-023-09554-w

PMID 37270535

发布时间 2024-09-19

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交